Tumor Necrosis Factor-α in Children with Human Immunodeficiency Virus Infection

References

• Tracey K J, Vlassara H, Cerami A. Cachectin/tumor necrosis factor. Lancet 1989; 1: 1122–1126
   PubMed Web of Science ®Google Scholar
• Tracey K J, Wei H, Manogue K R. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med. 1988; 167: 1211–1227
   PubMed Web of Science ®Google Scholar
• Tracey K J, Lowry S F, Fahey TJ, III. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987; 164: 415–422
   PubMedGoogle Scholar
• Ellaurie M, Rubinstein A. Elevated tumor necrosis factor (TNF) alpha in association with severe anemia in human immunodeficiency virus (HIV-1) infection and Mycobacterium avium intracellular (MAI) infection. Pediatr Hematol Oncol. 1995; 12(3)221–230
   Web of Science ®Google Scholar
• Girardin E, Grau G E, Dayer J M, Lombard P R, Lambert P H, J5 study group. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988; 319: 397–100
   PubMed Web of Science ®Google Scholar
• Mistchenko A S, Diez R A, Mariani A L. Cytokines in adenoviral disease in children: association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome. J Pediatr. 1994; 124: 714–720
   PubMed Web of Science ®Google Scholar
• Woo P. Cytokines in childhood rheumatic disease. Arch Dis Child 1993; 69: 547–549
   Google Scholar
• Vreugdenhill G, Lowenberg B, Van Eijk H G, Swaak A JG. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest. 1992; 22: 488–493
   Google Scholar
• Seckinger P, Zhang J H, Hauptmann B, Dayer J M. Characterization of tumor necrosis factor a (TNF-α) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990; 87: 5188–5192
   PubMed Web of Science ®Google Scholar
• Brockhaus M, Schoenfeld H J, Schlaeger E J, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 3127–3131
   PubMed Web of Science ®Google Scholar
• Engelman H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265: 1531–1536
   PubMed Web of Science ®Google Scholar
• Lotschen H, Pan Y E, Lahm H W, Gentz R. Molecular cloning and expression of the human 55 KD tumor necrosis factor receptor. Cell. 1990; 61: 361–370
   Google Scholar
• Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr. 1994; 124: 721–725
   PubMed Web of Science ®Google Scholar
• Cope A P, Aderka D, Doherty M. Increased levels of soluble tumor necrosis factor receptors in the sera and spinal fluid of patients with rheumatic diseases. Arthritis Rheum. 1992; 35: 1160–1169
   PubMed Web of Science ®Google Scholar
• Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-I associated myelopathy. J Neuroimmunol. 1994; 52: 33–40
   Google Scholar
• Van Zee K J, Kohno T, Fischer E, Rock C S, Moldawer L L, Lowry S F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-a in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845–4849
   PubMed Web of Science ®Google Scholar
• Girardin E, Roux-Lombard P, Graue G E. Imbalance between tumor necrosis factor alpha and soluble TNF receptor concentrations in severe meningococcemia. Immunology 1992; 76: 20–23
   PubMed Web of Science ®Google Scholar
• Van Deuren M, Van der Ven-Jongekrijg J, Demacker P N, Bartelink A K. Differential expression of pro-inflammatory cytokines and their inhibitors during the course of meningococcal infections. J. Infect Dis. 1994; 169: 157–161
   PubMed Web of Science ®Google Scholar
• Rogy M A, Coyle S M, Oldenburg H S. Persistently elevated soluble tumor necrosis factor receptor and interleukin-I receptor antagonist levels in critically ill patients. J Am Coll Surg. 1994; 178: 132–138
   PubMed Web of Science ®Google Scholar
• Horsburgh C R. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991; 324: 1332–1338
   PubMed Web of Science ®Google Scholar
• Bermudez L E, Stevens P, Kolonoski P, Wu M, Young L S. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol. 1989; 143: 2996–3000
   Google Scholar
• Matsuyyama T, Kobayachi N, Yamamoto N. Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease. AIDS. 1991; 5: 1405–1417
   Google Scholar
• Kalinkovich A, Engelmann H, Harpaz N. Elevated serum levels of soluble tumor necrosis factor receptor (S-TNF-R) in patients with HIV infection. Clin Exp Immunol. 1992; 89: 351–355
   PubMed Web of Science ®Google Scholar
• Bermudez L E. Production of transforming growth factor beta by Mycobacterium avium infected human macrophages is associated with unresponsiveness to IFN-gamma. J Immunology 1993; 150: 1838–1845
   PubMedGoogle Scholar
• Bermudez L E, Wu M, Petrofsky M, Young L S. Interleukin-6 antagonizes tumor necrosis factor mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun. 1992; 60: 4245–4252
   PubMed Web of Science ®Google Scholar
• Dinarello C A, Gelfand J A, Wolff S M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269: 1829–1835
   PubMed Web of Science ®Google Scholar
• Stone R. Search for sepsis drugs goes on despite past failures. Science. 1994; 264: 365–367
   PubMed Web of Science ®Google Scholar